Once-a-day administration of everolimus, cyclosporine, and steroid after renal transplantation: a review of the rationale.
The Evidence study (EVerolImus once-a-Day rEgimen with Neoral versus Corticosteroid Elimination) sought to compare once-a-day administration with steroid withdrawal versus twice-daily administration among de novo kidney transplant recipients treated with everolimus, cyclosporine, and steroids. This article describes the study design and rationale of once-daily administration and steroid withdrawal among recipients of de novo kidney transplants treated with everolimus and cyclosporine.
Corbetta
G
G
Medical Department, Novartis Farma SpA, Origgio, Va, Italy. giuseppe.corbetta@novartis.com
Ponticelli
C
C
D000305:Adrenal Cortex Hormones / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016572:Cyclosporine / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D000068338:Everolimus; D019317:Evidence-Based Medicine; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics / Q000627:therapeutic use; D007408:Intestinal Absorption; D016030:Kidney Transplantation / Q000276:immunology*; D010349:Patient Compliance; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D013997:Time Factors
D000305:Adrenal Cortex Hormones; D007166:Immunosuppressive Agents; D016572:Cyclosporine; D000068338:Everolimus; D020123:Sirolimus